Response to ‘Cardiotoxicity associated with use of intavenous haloperidol’

Australian and New Zealand Journal of Psychiatry

Volumn 33, Issue 6, 1999, Pages 943-944

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; HALOPERIDOL; NEUROLEPTIC AGENT;

CHEMICALLY INDUCED DISORDER; CONSCIOUS SEDATION; EMERGENCY HEALTH SERVICE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NOTE; PRACTICE GUIDELINE; PSYCHOSIS; RISK FACTOR; TORSADE DES POINTES;

ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CONSCIOUS SEDATION; EMERGENCY SERVICES, PSYCHIATRIC; HALOPERIDOL; HUMANS; INFUSIONS, INTRAVENOUS; PRACTICE GUIDELINES; PSYCHOTIC DISORDERS; RISK FACTORS; TORSADES DE POINTES;

EID: 0033252022     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/0004867990414     Document Type: Article

References (5)

1. Victorian Medical Postgraduate Foundation. Psychotropic drug guidelines. 3rd ed. Melbourne: Victorian Medical Postgraduate Foundation, 1995.
2. Furrows DC. Cardiotoxicity associated with use of intravenous haloperidol [letter]. Australian and New Zealand Journal of Psychiatry 1999; 33:284.
3. Hunt N, Stern T. The association between intravenous haloperidol and Torsades de Pointes. Psychosomatics 1995; 36:541–549.
4. Sharma ND, Rosman HS, Padhi D, Tisdale JE. Torsades de Pointes associated with intravenous haloperidol in critically ill patients. American Journal of Cardiology 1998; 81:238–240.
5. Lawrence KR, Nasraway SA. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy 1997; 17:531–537.